138 related articles for article (PubMed ID: 2113224)
21. Pharmacokinetics of ceftazidime in CAPD-related peritonitis.
Booranalertpaisarn V; Eiam-Ong S; Wittayalertpanya S; Kanjanabutr T; Na Ayudhya DP
Perit Dial Int; 2003; 23(6):574-9. PubMed ID: 14703199
[TBL] [Abstract][Full Text] [Related]
22. [Pharmacokinetics of vancomycin in chronic renal failure patients in continuous ambulatory peritoneal dialysis (CAPD) after intra-abdominal administration].
Mounier M; Benevent D; Denis F
Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):542-4. PubMed ID: 3911152
[TBL] [Abstract][Full Text] [Related]
23. Multiple-dose-kinetics of ofloxacin after intraperitoneal application in CAPD patients.
Kampf D; Borner K; Hain H; Conrad W
Perit Dial Int; 1991; 11(4):317-21. PubMed ID: 1751596
[TBL] [Abstract][Full Text] [Related]
24. Unidirectional absorption of gentamicin from the peritoneum during continuous ambulatory peritoneal dialysis.
Somani P; Shapiro RS; Stockard H; Higgins JT
Clin Pharmacol Ther; 1982 Jul; 32(1):113-21. PubMed ID: 7083725
[TBL] [Abstract][Full Text] [Related]
25. Absorption of intraperitoneal antibiotics.
Morse GD; Apicella MA; Walshe JJ
Drug Intell Clin Pharm; 1988 Jan; 22(1):58-61. PubMed ID: 3349922
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of cefradine, sulfamethoxazole and trimethoprim and their metabolites in a patient with peritonitis undergoing continuous ambulatory peritoneal dialysis.
Martea M; Hekster YA; Vree TB; Voets AJ; Berden JH
Pharm Weekbl Sci; 1987 Apr; 9(2):110-6. PubMed ID: 3495778
[TBL] [Abstract][Full Text] [Related]
27. Serum CA-125 level in end-stage renal disease patients maintained on chronic peritoneal dialysis or hemodialysis: the effect of continuous presence of peritoneal fluid, peritonitis, and peritoneal catheter implantation.
Bastani B; Chu N
Am J Nephrol; 1995; 15(6):468-72. PubMed ID: 8546167
[TBL] [Abstract][Full Text] [Related]
28. Vancomycin and tobramycin in the treatment of CAPD peritonitis.
Gruer LD; Turney JH; Curley J; Michael J; Adu D
Nephron; 1985; 41(3):279-82. PubMed ID: 4058628
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of once daily intra-peritoneal aztreonam and vancomycin in the treatment of CAPD peritonitis.
Brown J; Altmann P; Cunningham J; Shaw E; Marsh F
J Antimicrob Chemother; 1990 Jan; 25(1):141-7. PubMed ID: 2318749
[TBL] [Abstract][Full Text] [Related]
30. [A rare cause of peritoneal dialysis-related peritonitis: Haemophilus influenzae].
Unal A; Perçin DE; Sipahioğlu MH; Kavuncuoğlu F; Tokgöz B; Oymak O; Utaş C
Mikrobiyol Bul; 2009 Jul; 43(3):477-80. PubMed ID: 19795624
[TBL] [Abstract][Full Text] [Related]
31. Probenecid effect on cefuroxime pharmacokinetics in calves.
Soback S; Ziv G; Kokue EI
J Vet Pharmacol Ther; 1989 Mar; 12(1):87-93. PubMed ID: 2704066
[TBL] [Abstract][Full Text] [Related]
32. Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment.
Brink HS; Huisman RM; Geerlings W; de Jong PE
Adv Perit Dial; 1994; 10():179-82. PubMed ID: 7999822
[TBL] [Abstract][Full Text] [Related]
33. [Pharmacokinetics of piperacillin during continuous ambulatory peritoneal dialysis].
Ryckelynck JP; Debruyne D; Hurault De Ligny B; Moulin M
Pathol Biol (Paris); 1988 May; 36(5):507-10. PubMed ID: 3043348
[TBL] [Abstract][Full Text] [Related]
34. Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.
Keller E; Reetze P; Schollmeyer P
Clin Pharmacokinet; 1990 Feb; 18(2):104-17. PubMed ID: 2180611
[TBL] [Abstract][Full Text] [Related]
35. [The effect of the number of peritonitis episodes on peritoneal membrane function].
Jovanović D; Nesić V; Dimitrijević Z
Srp Arh Celok Lek; 1999; 127(1-2):28-31. PubMed ID: 10377837
[TBL] [Abstract][Full Text] [Related]
36. Netilmycin and vancomycin in the treatment of peritonitis in CAPD patients.
Were AJ; Marsden A; Tooth A; Ramsden R; Mistry CD; Gokal R
Clin Nephrol; 1992 Apr; 37(4):209-13. PubMed ID: 1582059
[TBL] [Abstract][Full Text] [Related]
37. Peritonitis caused by Monilia sitophila in a patient undergoing peritoneal dialysis.
Radix AE; Bieluch VM; Graeber CW
Int J Artif Organs; 1996 Apr; 19(4):218-20. PubMed ID: 8786172
[TBL] [Abstract][Full Text] [Related]
38. [CAPD related peritonitis].
Kawada Y; Kuriyama M
Nihon Rinsho; 1992 Jan; 50 Suppl():757-62. PubMed ID: 1578762
[No Abstract] [Full Text] [Related]
39. Use of bolus intraperitoneal aminoglycosides for treating peritonitis in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis.
Mars RL; Moles K; Pope K; Hargrove P
Adv Perit Dial; 2000; 16():280-4. PubMed ID: 11045311
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of clindamycin in the plasma and dialysate after intraperitoneal administration of clindamycin phosphoester to patients on continuous ambulatory peritoneal dialysis: an open-label, prospective, single-dose, two-institution study.
Chang MJ; Namgung H; Choi HD; Song YR; Kim SG; Oh JM; Shin WG
Basic Clin Pharmacol Toxicol; 2012 Jun; 110(6):504-9. PubMed ID: 22151828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
